What can independent research for mesothelioma achieve to treat this orphan disease?-Reference-Cited by-同舟云学术

What can independent research for mesothelioma achieve to treat this orphan disease?

Published:2019-07-01 Issue:8 Volume:28 Page:719-732
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Guazzelli Alice¹,Meysami Parisa¹,Bakker Emyr²,Bonanni Ezio³,Demonacos Constantinos⁴,Krstic-Demonacos Marija¹,Mutti Luciano⁵

Affiliation:

1. School of Environment and Life Sciences, University of Salford, Salford, UK

2. School of Medicine, University of Central Lancashire, Preston, UK

3. National Asbestos Observatory, Rome, Italy

4. Faculty of Biology, Medicine and Health, School of Health Sciences, University of Manchester, Manchester, UK

5. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2019.1638363

Reference126 articles.

1. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

2. Therapies currently in Phase II trials for malignant pleural mesothelioma

3. SV40 and cell cycle perturbations in malignant mesothelioma

4. Germline BAP1 mutations predispose to malignant mesothelioma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model;Frontiers in Immunology;2023-11-23

2. Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study;Journal of Thoracic Oncology;2023-06

3. Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils the Characteristics of the Immune Microenvironment and Prognosis Signature in Prostate Cancer;Journal of Oncology;2022-07-19

4. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma;Cancers;2021-05-12

5. S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma;Cancers;2020-04-10